We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+1.17%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$119M
AUM Growth
-$35.2M
Cap. Flow
-$21.8M
Cap. Flow %
-18.32%
Top 10 Hldgs %
65.31%
Holding
42
New
9
Increased
12
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
CRBP icon
Corbus Pharmaceuticals
CRBP
+$2.71M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$2.62M
3
BBOT
BridgeBio Oncology
BBOT
+$1.83M
4
ARGX icon
argenx
ARGX
+$1.53M
5
KURA icon
Kura Oncology
KURA
+$1.5M

Top Sells

Rank Stock Value
1
APLT
Applied Therapeutics
APLT
+$5.39M
2
IRON icon
Disc Medicine
IRON
+$4.78M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$4.71M
4
CLDX icon
Celldex Therapeutics
CLDX
+$4.57M
5
HLVX
HilleVax
HLVX
+$4.17M

Sector Composition

Rank Sector Weight
1 Healthcare 99.58%
2 Financials 0.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCUL icon
1
Ocular Therapeutix
OCUL
$1.84B
$19M 15.96%
2,771,130
+135,843
+5% +$839K
ELVN icon
2
Enliven Therapeutics
ELVN
$4.15B
$9.29M 7.83%
397,698
+1,599
+0.4% +$33.7K
PCVX icon
3
Vaxcyte
PCVX
$7.73B
$8.34M 7.02%
110,400
+5,570
+5% +$379K
DYN icon
4
Dyne Therapeutics
DYN
$4.71B
$7.5M 6.32%
212,500
+28,000
+15% +$814K
PRAX icon
5
Praxis Precision Medicines
PRAX
$8.52B
$6.8M 5.73%
164,431
+2,129
+1% +$101K
CRNX icon
6
Crinetics Pharmaceuticals
CRNX
$8.87B
$6.05M 5.1%
135,141
+56,738
+72% +$2.62M
RCKT icon
7
Rocket Pharmaceuticals
RCKT
$372M
$5.39M 4.54%
250,370
-76,417
-23% -$1.76M
TSHA icon
8
Taysha Gene Therapies
TSHA
$1.66B
$5.22M 4.4%
2,330,937
-1,002,396
-30% -$2.92M
RVMD icon
9
Revolution Medicines
RVMD
$38.8B
$5.16M 4.35%
133,000
-10,777
-7% -$403K
INSM icon
10
Insmed
INSM
$21.3B
$4.83M 4.07%
72,100
+10,382
+17% +$403K
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.68B
$4.34M 3.66%
27,500
-36,662
-57% -$4.71M
TRML
12
DELISTED
Tourmaline Bio
TRML
$3.47M 2.92%
269,614
+8,506
+3% +$137K
AGIO icon
13
Agios Pharmaceuticals
AGIO
$1.82B
$3.39M 2.86%
78,700
+23,438
+42% +$846K
KURA icon
14
Kura Oncology
KURA
$816M
$3.36M 2.83%
163,000
+73,000
+81% +$1.5M
MRSN
15
DELISTED
Mersana Therapeutics
MRSN
$3.34M 2.82%
66,520
-20,065
-23% -$1.45M
CRBP icon
16
Corbus Pharmaceuticals
CRBP
$165M
$2.92M 2.46%
+64,500
New +$2.71M
WHWK
17
Whitehawk Therapeutics
WHWK
$196M
$2.7M 2.27%
1,849,402
– –
VRDN icon
18
Viridian Therapeutics
VRDN
$2.13B
$2.59M 2.19%
199,433
– –
TERN
19
DELISTED
Terns Pharmaceuticals
TERN
$2.51M 2.12%
369,280
-95,799
-21% -$580K
MREO
20
Mereo BioPharma
MREO
$50.4M
$2.44M 2.05%
677,000
+279,116
+70% +$904K
ACLX
21
DELISTED
Arcellx
ACLX
$2.33M 1.96%
42,200
+7,700
+22% +$419K
BBOT
22
BridgeBio Oncology
BBOT
$661M
$1.82M 1.53%
+177,836
New +$1.83M
ARGX icon
23
argenx
ARGX
$52B
$1.72M 1.45%
+4,000
New +$1.53M
TRVI icon
24
Trevi Therapeutics
TRVI
$2.54B
$775K 0.65%
+260,000
New +$722K
CELC icon
25
Celcuity
CELC
$4.28B
$737K 0.62%
+45,000
New +$753K
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Acuta Capital Partners held 42 positions worth $119M, down 23% from $154M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Acuta Capital Partners withdrew a net $21.8M in Q2 2024, closing 9 positions and reducing 9 holdings. Its most notable exit was Applied Therapeutics, an estimated $5.39M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Acuta Capital Partners opened a new position in Corbus Pharmaceuticals worth $2.92M.

  • Acuta Capital Partners's largest Q2 2024 buy was Corbus Pharmaceuticals: 64,500 shares worth $2.92M.
  • Acuta Capital Partners added most to Crinetics Pharmaceuticals in Q2 2024, an estimated $2.62M increase.
  • Acuta Capital Partners's biggest Q2 2024 reduction was Sarepta Therapeutics, cutting an estimated $4.71M.
  • Acuta Capital Partners fully exited Applied Therapeutics in Q2 2024, selling an estimated $5.39M.
  • Acuta Capital Partners's ten largest holdings make up 65% of its $119M portfolio in Q2 2024.
  • Acuta Capital Partners opened 9 new positions and closed 9 in Q2 2024.
  • Acuta Capital Partners's portfolio value fell 23% quarter-over-quarter to $119M.

Based on Acuta Capital Partners's 13F filing for Q2 2024, filed 14 Aug 2024.